J&J's blockbuster hopeful erdafitinib gets 'breakthrough' moniker
Janssen has snagged the FDA’s breakthrough status on its solid tumor drug candidate erdafitinib, putting J&J one step closer to its lofty goal of bringing …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
